Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5081102
Max Phase: Preclinical
Molecular Formula: C49H65N7O6S
Molecular Weight: 880.17
Molecule Type: Unknown
Associated Items:
ID: ALA5081102
Max Phase: Preclinical
Molecular Formula: C49H65N7O6S
Molecular Weight: 880.17
Molecule Type: Unknown
Associated Items:
Canonical SMILES: Cc1ncsc1-c1ccc(CNC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)CCCCCCCCCCCCC(=O)Nc2ccc(C(=O)Nc3ccccc3N)cc2)C(C)(C)C)cc1
Standard InChI: InChI=1S/C49H65N7O6S/c1-33-44(63-32-52-33)35-23-21-34(22-24-35)30-51-47(61)41-29-38(57)31-56(41)48(62)45(49(2,3)4)55-43(59)20-14-12-10-8-6-5-7-9-11-13-19-42(58)53-37-27-25-36(26-28-37)46(60)54-40-18-16-15-17-39(40)50/h15-18,21-28,32,38,41,45,57H,5-14,19-20,29-31,50H2,1-4H3,(H,51,61)(H,53,58)(H,54,60)(H,55,59)/t38-,41+,45-/m1/s1
Standard InChI Key: AHURBROGQUEMLW-XVYMMXEDSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 880.17 | Molecular Weight (Monoisotopic): 879.4717 | AlogP: 8.38 | #Rotatable Bonds: 22 |
Polar Surface Area: 195.85 | Molecular Species: NEUTRAL | HBA: 9 | HBD: 6 |
#RO5 Violations: 3 | HBA (Lipinski): 13 | HBD (Lipinski): 7 | #RO5 Violations (Lipinski): 4 |
CX Acidic pKa: 12.67 | CX Basic pKa: 3.24 | CX LogP: 6.64 | CX LogD: 6.64 |
Aromatic Rings: 4 | Heavy Atoms: 63 | QED Weighted: 0.03 | Np Likeness Score: -0.66 |
1. Smalley JP, Baker IM, Pytel WA, Lin LY, Bowman KJ, Schwabe JWR, Cowley SM, Hodgkinson JT.. (2022) Optimization of Class I Histone Deacetylase PROTACs Reveals that HDAC1/2 Degradation is Critical to Induce Apoptosis and Cell Arrest in Cancer Cells., 65 (7.0): [PMID:35293758] [10.1021/acs.jmedchem.1c02179] |
Source(1):